<!DOCTYPE html>
<html lang="en"><head><meta charset="UTF-8"/><meta name="viewport" content="width=device-width, initial-scale=1.0"/><title>Drug-Target Networks · OptimShortestPaths.jl</title><meta name="title" content="Drug-Target Networks · OptimShortestPaths.jl"/><meta property="og:title" content="Drug-Target Networks · OptimShortestPaths.jl"/><meta property="twitter:title" content="Drug-Target Networks · OptimShortestPaths.jl"/><meta name="description" content="Documentation for OptimShortestPaths.jl."/><meta property="og:description" content="Documentation for OptimShortestPaths.jl."/><meta property="twitter:description" content="Documentation for OptimShortestPaths.jl."/><meta property="og:url" content="https://danielchen26.github.io/OptimShortestPaths.jl/examples/drug_target_network/"/><meta property="twitter:url" content="https://danielchen26.github.io/OptimShortestPaths.jl/examples/drug_target_network/"/><link rel="canonical" href="https://danielchen26.github.io/OptimShortestPaths.jl/examples/drug_target_network/"/><script data-outdated-warner src="../../assets/warner.js"></script><link href="https://cdnjs.cloudflare.com/ajax/libs/lato-font/3.0.0/css/lato-font.min.css" rel="stylesheet" type="text/css"/><link href="https://cdnjs.cloudflare.com/ajax/libs/juliamono/0.050/juliamono.min.css" rel="stylesheet" type="text/css"/><link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.2/css/fontawesome.min.css" rel="stylesheet" type="text/css"/><link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.2/css/solid.min.css" rel="stylesheet" type="text/css"/><link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.2/css/brands.min.css" rel="stylesheet" type="text/css"/><link href="https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.16.8/katex.min.css" rel="stylesheet" type="text/css"/><script>documenterBaseURL="../.."</script><script src="https://cdnjs.cloudflare.com/ajax/libs/require.js/2.3.6/require.min.js" data-main="../../assets/documenter.js"></script><script src="../../search_index.js"></script><script src="../../siteinfo.js"></script><script src="../../../versions.js"></script><link class="docs-theme-link" rel="stylesheet" type="text/css" href="../../assets/themes/catppuccin-mocha.css" data-theme-name="catppuccin-mocha"/><link class="docs-theme-link" rel="stylesheet" type="text/css" href="../../assets/themes/catppuccin-macchiato.css" data-theme-name="catppuccin-macchiato"/><link class="docs-theme-link" rel="stylesheet" type="text/css" href="../../assets/themes/catppuccin-frappe.css" data-theme-name="catppuccin-frappe"/><link class="docs-theme-link" rel="stylesheet" type="text/css" href="../../assets/themes/catppuccin-latte.css" data-theme-name="catppuccin-latte"/><link class="docs-theme-link" rel="stylesheet" type="text/css" href="../../assets/themes/documenter-dark.css" data-theme-name="documenter-dark" data-theme-primary-dark/><link class="docs-theme-link" rel="stylesheet" type="text/css" href="../../assets/themes/documenter-light.css" data-theme-name="documenter-light" data-theme-primary/><script src="../../assets/themeswap.js"></script></head><body><div id="documenter"><nav class="docs-sidebar"><div class="docs-package-name"><span class="docs-autofit"><a href="../../">OptimShortestPaths.jl</a></span></div><button class="docs-search-query input is-rounded is-small is-clickable my-2 mx-auto py-1 px-2" id="documenter-search-query">Search docs (Ctrl + /)</button><ul class="docs-menu"><li><a class="tocitem" href="../../">Home</a></li><li><span class="tocitem">Manual</span><ul><li><a class="tocitem" href="../../manual/getting_started/">Getting Started</a></li><li><a class="tocitem" href="../../manual/transformation/">Problem Transformation</a></li><li><a class="tocitem" href="../../manual/multiobjective/">Multi-Objective Optimization</a></li><li><a class="tocitem" href="../../manual/domains/">Domain Applications</a></li></ul></li><li><span class="tocitem">Examples</span><ul><li><a class="tocitem" href="../">Overview</a></li><li><a class="tocitem" href="../comprehensive_demo/">Comprehensive Demo</a></li><li class="is-active"><a class="tocitem" href>Drug-Target Networks</a></li><li><a class="tocitem" href="../metabolic_pathway/">Metabolic Pathways</a></li><li><a class="tocitem" href="../treatment_protocol/">Treatment Protocols</a></li><li><a class="tocitem" href="../supply_chain/">Supply Chain Optimization</a></li></ul></li><li><a class="tocitem" href="../../api/">API Reference</a></li><li><a class="tocitem" href="../../benchmarks/">Benchmarks</a></li></ul><div class="docs-version-selector field has-addons"><div class="control"><span class="docs-label button is-static is-size-7">Version</span></div><div class="docs-selector control is-expanded"><div class="select is-fullwidth is-size-7"><select id="documenter-version-selector"></select></div></div></div></nav><div class="docs-main"><header class="docs-navbar"><a class="docs-sidebar-button docs-navbar-link fa-solid fa-bars is-hidden-desktop" id="documenter-sidebar-button" href="#"></a><nav class="breadcrumb"><ul class="is-hidden-mobile"><li><a class="is-disabled">Examples</a></li><li class="is-active"><a href>Drug-Target Networks</a></li></ul><ul class="is-hidden-tablet"><li class="is-active"><a href>Drug-Target Networks</a></li></ul></nav><div class="docs-right"><a class="docs-navbar-link" href="https://github.com/danielchen26/OptimShortestPaths.jl" title="View the repository on GitHub"><span class="docs-icon fa-brands"></span><span class="docs-label is-hidden-touch">GitHub</span></a><a class="docs-navbar-link" href="https://github.com/danielchen26/OptimShortestPaths.jl/blob/main/docs/src/examples/drug_target_network.md#" title="Edit source on GitHub"><span class="docs-icon fa-solid"></span></a><a class="docs-settings-button docs-navbar-link fa-solid fa-gear" id="documenter-settings-button" href="#" title="Settings"></a><a class="docs-article-toggle-button fa-solid fa-chevron-up" id="documenter-article-toggle-button" href="javascript:;" title="Collapse all docstrings"></a></div></header><article class="content" id="documenter-page"><h1>Drug-Target Network Analysis Dashboard</h1><h2>Executive Summary</h2><p>This dashboard presents comprehensive results from applying the DMY shortest-path algorithm to drug-target networks, including both <strong>single-objective</strong> optimization and <strong>multi-objective Pareto front</strong> analysis.</p><p><strong>Key Findings</strong>:</p><ol><li><strong>Single-objective</strong>: Celecoxib remains the most COX-2 selective option (~3.7× vs COX-1) while all sample drugs reach every target</li><li><strong>Multi-objective</strong>: Seven Pareto-optimal drug pathways span efficacy 40–98%, toxicity 3–70%, cost <span>$5–$</span>200, and onset 1.0–7.5 h</li><li><strong>Performance</strong>: DMY achieves ≈4.8× speedup over Dijkstra at n=5000 for sparse graphs (k = ⌈n^{1/3}⌉)</li></ol><h3>Reproducibility</h3><p>All scripts accept a deterministic seed via either <code>OPTIM_SP_SEED</code> or a <code>--seed=</code> flag. Example:</p><pre><code class="language-bash hljs">OPTIM_SP_SEED=2024 julia --project=. drug_target_network.jl</code></pre><p>If no seed is provided, the default (<code>42</code>) is used. Use the same flag when generating figures to ensure the plots and tables align with the narrative below.</p><hr/><h2>Part 1: Single-Objective Analysis</h2><h3>Figure 1: Drug-Target Binding Affinity Matrix</h3><p><img src="figures/binding_affinity_heatmap.png" alt="Binding Affinity Heatmap"/></p><p><strong>Interpretation</strong>: </p><ul><li>Matrix shows normalized binding affinities (0=no binding, 1=perfect binding)</li><li>Celecoxib: Strong COX-2 (0.95), weak COX-1 (0.05) → Selective inhibitor</li><li>Aspirin: Strong COX-1 (0.85), moderate COX-2 (0.45) → Non-selective</li></ul><h3>Figure 2: COX-2/COX-1 Selectivity Profile</h3><p><img src="figures/cox_selectivity.png" alt="COX Selectivity"/></p><p><strong>Clinical Significance</strong>:</p><table><tr><th style="text-align: right">Drug</th><th style="text-align: right">Selectivity</th><th style="text-align: right">Interpretation</th><th style="text-align: right">GI Risk</th></tr><tr><td style="text-align: right">Celecoxib</td><td style="text-align: right">3.7×</td><td style="text-align: right">Strong COX-2 preference</td><td style="text-align: right">Low</td></tr><tr><td style="text-align: right">Ibuprofen</td><td style="text-align: right">2.0×</td><td style="text-align: right">Mild COX-2 preference</td><td style="text-align: right">Low-Moderate</td></tr><tr><td style="text-align: right">Acetaminophen</td><td style="text-align: right">1.2×</td><td style="text-align: right">Slight COX-2 tilt</td><td style="text-align: right">Low</td></tr><tr><td style="text-align: right">Aspirin</td><td style="text-align: right">0.7×</td><td style="text-align: right">COX-1 biased (non-selective)</td><td style="text-align: right">Higher</td></tr></table><hr/><h2>Part 2: Multi-Objective Pareto Front Analysis</h2><h3>The Challenge</h3><p>Real-world drug selection involves multiple competing objectives:</p><ul><li><strong>Efficacy</strong>: How well does it work?</li><li><strong>Toxicity</strong>: What are the side effects?</li><li><strong>Cost</strong>: Can patients afford it?</li><li><strong>Time</strong>: How quickly does it act?</li></ul><h3>Figure 3: 2D Pareto Front Projections</h3><p><img src="figures/drug_pareto_front.png" alt="Pareto Front 2D"/></p><p><strong>Four critical trade-offs visualized</strong>:</p><ol><li><strong>Efficacy vs Toxicity</strong>: Higher efficacy drugs have more side effects</li><li><strong>Efficacy vs Cost</strong>: Better drugs cost more</li><li><strong>Toxicity vs Cost</strong>: Safer drugs are expensive</li><li><strong>Time vs Efficacy</strong>: Fast-acting drugs may be less effective</li></ol><h3>Figure 4: 3D Pareto Front Visualization</h3><p><img src="figures/drug_pareto_3d.png" alt="Pareto Front 3D"/></p><p><strong>3D Trade-off Space</strong>: This plot shows the three most critical objectives simultaneously:</p><ul><li><strong>X-axis (Efficacy)</strong>: Treatment effectiveness (0–100 %)</li><li><strong>Y-axis (Toxicity)</strong>: Side effect severity (0–100 %)</li><li><strong>Z-axis (Cost)</strong>: Price in dollars (<span>$5–$</span>200 across the frontier)</li></ul><p>Legend highlights:</p><ul><li><strong>Red sphere — “Max Efficacy”</strong>: Morphine-like → MOR (Solution 5) delivers ~98 % efficacy in 1 h at the cost of high toxicity (70 %) and 50.0</li><li><strong>Green sphere — “Min Toxicity”</strong>: Ibuprofen-like → COX-2 (Solution 3) keeps toxicity at 10 % with moderate efficacy (~60 %) and 15 cost.</li><li><strong>Orange sphere — “Min Cost”</strong>: Aspirin-like → COX-1 (Solution 1) is the 5 budget choice with 85 % efficacy and 30 % toxicity.</li><li><strong>Purple hexagon — “Knee Point”</strong>: Morphine-like → COX-1 (Solution 4) marks the steepest trade-off change (95 % efficacy, 60 % toxicity, 50).</li></ul><p>The remaining Pareto solutions (grey) illustrate the continuous trade-offs between these extremes.</p><h3>Representative Pareto-Optimal Solutions</h3><table><tr><th style="text-align: right">Solution</th><th style="text-align: right">Drug→Target</th><th style="text-align: right">Efficacy</th><th style="text-align: right">Toxicity</th><th style="text-align: right">Cost</th><th style="text-align: right">Time</th><th style="text-align: right"><strong>When to Use</strong></th></tr><tr><td style="text-align: right">1</td><td style="text-align: right">Aspirin-like → COX-1</td><td style="text-align: right">85%</td><td style="text-align: right">30%</td><td style="text-align: right">5</td><td style="text-align: right">2.5 h</td><td style="text-align: right"><strong>Baseline analgesia</strong> – inexpensive, moderate toxicity</td></tr><tr><td style="text-align: right">2</td><td style="text-align: right">Ibuprofen-like → COX-1</td><td style="text-align: right">65%</td><td style="text-align: right">15%</td><td style="text-align: right">15</td><td style="text-align: right">3.5 h</td><td style="text-align: right"><strong>General pain</strong> – balanced efficacy/toxicity</td></tr><tr><td style="text-align: right">3</td><td style="text-align: right">Ibuprofen-like → COX-2</td><td style="text-align: right">60%</td><td style="text-align: right">10%</td><td style="text-align: right">15</td><td style="text-align: right">4.0 h</td><td style="text-align: right"><strong>Elderly / GI risk</strong> – prioritize low toxicity</td></tr><tr><td style="text-align: right">4</td><td style="text-align: right">Morphine-like → COX-1</td><td style="text-align: right">95%</td><td style="text-align: right">60%</td><td style="text-align: right">50</td><td style="text-align: right">1.5 h</td><td style="text-align: right"><strong>Severe pain</strong> – high efficacy, monitor side effects</td></tr><tr><td style="text-align: right">5</td><td style="text-align: right">Morphine-like → MOR</td><td style="text-align: right">98%</td><td style="text-align: right">70%</td><td style="text-align: right">50</td><td style="text-align: right">1.0 h</td><td style="text-align: right"><strong>Emergency trauma</strong> – fastest, most potent relief</td></tr><tr><td style="text-align: right">6</td><td style="text-align: right">Biologic-like → COX-2</td><td style="text-align: right">45%</td><td style="text-align: right">5%</td><td style="text-align: right">200</td><td style="text-align: right">6.5 h</td><td style="text-align: right"><strong>High-risk patients</strong> – ultra-low toxicity despite high cost</td></tr><tr><td style="text-align: right">7</td><td style="text-align: right">Biologic-like → MOR</td><td style="text-align: right">40%</td><td style="text-align: right">3%</td><td style="text-align: right">200</td><td style="text-align: right">7.5 h</td><td style="text-align: right"><strong>Neuropathic pain</strong> – minimal adverse effects, accepts slow onset</td></tr></table><p>High-cost biologic options (Solutions 6–7) reduce toxicity to ≤5% while maintaining moderate efficacy (40–45%), but require 200 outlay and a 6.5–7.5 h onset.</p><h3>How to Select from Pareto Front</h3><h4>Method 1: Weighted Sum Approach</h4><p>Because this problem mixes maximize (efficacy) and minimize (toxicity/cost/time) objectives, a direct weighted sum requires transforming the maximize objectives into costs (e.g., use <code>1 - efficacy</code>). The example scripts keep this method disabled by default to avoid misleading scoring—convert objectives first if you need a scalar ranking.</p><h4>Method 2: Constraint-Based Selection</h4><p>Set hard limits on certain objectives:</p><ul><li>Toxicity ≤ 30% → Aspirin-like → COX-1 (Solution 1) is the lone candidate</li><li>Cost ≤ 20 → Aspirin-like (Solution 1), Ibuprofen-like COX-1/COX-2 (Solutions 2–3)</li><li>Both constraints → Ibuprofen-like COX-1/COX-2 trade a little efficacy for safety</li></ul><h4>Method 3: Knee Point Selection</h4><p>The current knee point is the Morphine-like → MOR pathway (Solution 5):</p><ul><li>Maximum efficacy (≈98%) with 1 h onset</li><li>Accept high toxicity (70%) and higher cost (50)</li><li>Suitable when rapid, potent analgesia outweighs side-effect risk</li></ul><hr/><h2>Part 3: Algorithm Performance</h2><h3>Figure 5: Algorithm Performance Benchmark</h3><p><img src="figures/performance_analysis.png" alt="Performance Analysis"/></p><p>Benchmark results from <code>benchmark_results.txt</code> with <code>k = ⌈n^{1/3}⌉</code>:</p><table><tr><th style="text-align: right">Graph Size</th><th style="text-align: right">DMY (ms) ±95% CI</th><th style="text-align: right">Dijkstra (ms) ±95% CI</th><th style="text-align: right">Speedup</th></tr><tr><td style="text-align: right">200</td><td style="text-align: right">0.081 ± 0.002</td><td style="text-align: right">0.025 ± 0.001</td><td style="text-align: right">0.31×</td></tr><tr><td style="text-align: right">500</td><td style="text-align: right">0.426 ± 0.197</td><td style="text-align: right">0.167 ± 0.004</td><td style="text-align: right">0.39×</td></tr><tr><td style="text-align: right">1,000</td><td style="text-align: right">1.458 ± 1.659</td><td style="text-align: right">0.641 ± 0.008</td><td style="text-align: right">0.44×</td></tr><tr><td style="text-align: right">2,000</td><td style="text-align: right">1.415 ± 0.094</td><td style="text-align: right">2.510 ± 0.038</td><td style="text-align: right"><strong>1.77×</strong></td></tr><tr><td style="text-align: right">5,000</td><td style="text-align: right">3.346 ± 0.105</td><td style="text-align: right">16.028 ± 0.241</td><td style="text-align: right"><strong>4.79×</strong></td></tr></table><p><strong>Key Insights</strong>:</p><ul><li>Small graphs (n &lt; 1,000): Dijkstra is faster (DMY at 0.3×–0.4× speed)</li><li>Crossover around n ≈ 2,000 vertices for sparse graphs</li><li>Large sparse graphs (n ≥ 2,000): DMY delivers ≈1.8×–4.8× speedups</li><li>Results match the canonical <code>benchmark_results.txt</code> file</li></ul><hr/><h2>Key Takeaways</h2><h3>Single vs Multi-Objective</h3><ul><li><strong>Single-objective</strong>: One &quot;best&quot; path (e.g., Celecoxib for COX-2 selectivity)</li><li><strong>Multi-objective</strong>: Seven non-dominated solutions on the Pareto front</li><li><strong>Real-world</strong>: Multi-objective reflects clinical reality better</li></ul><h3>Algorithm Performance</h3><ul><li><strong>Small graphs (n &lt; 1,000)</strong>: Dijkstra is faster (DMY at 0.3×–0.4× speed)</li><li><strong>Large sparse graphs (n ≥ 2,000)</strong>: DMY delivers ≈1.8×–4.8× speedups</li><li><strong>Sparse networks</strong>: DMY&#39;s sweet spot (k = ⌈n^{1/3}⌉)</li></ul><h3>Clinical Impact</h3><ul><li><strong>No universal &quot;best&quot; drug</strong>: Context determines optimal choice</li><li><strong>Trade-offs are explicit</strong>: Pareto front visualizes all options</li><li><strong>Personalized medicine enabled</strong>: Match solution to patient</li></ul><hr/><h2>Reproducibility</h2><p>Generate all figures:</p><pre><code class="language-bash hljs">julia --project=. generate_figures.jl</code></pre><p>Run complete analysis:</p><pre><code class="language-bash hljs">julia --project=. drug_target_network.jl</code></pre><hr/><h2>References</h2><ol><li>Duan, R., Mao, J., &amp; Yin, Q. (2025). &quot;Breaking the Sorting Barrier for Directed SSSP&quot;. STOC 2025.</li><li>Multi-objective optimization: Ehrgott, M. (2005). &quot;Multicriteria Optimization&quot;. Springer.</li><li>Drug data: ChEMBL and DrugBank databases.</li></ol><hr/><p><em>Dashboard generated using DMYShortestPath.jl - Implementing the breakthrough DMY algorithm with multi-objective extensions</em></p></article><nav class="docs-footer"><a class="docs-footer-prevpage" href="../comprehensive_demo/">« Comprehensive Demo</a><a class="docs-footer-nextpage" href="../metabolic_pathway/">Metabolic Pathways »</a><div class="flexbox-break"></div><p class="footer-message">Powered by <a href="https://github.com/JuliaDocs/Documenter.jl">Documenter.jl</a> and the <a href="https://julialang.org/">Julia Programming Language</a>.</p></nav></div><div class="modal" id="documenter-settings"><div class="modal-background"></div><div class="modal-card"><header class="modal-card-head"><p class="modal-card-title">Settings</p><button class="delete"></button></header><section class="modal-card-body"><p><label class="label">Theme</label><div class="select"><select id="documenter-themepicker"><option value="auto">Automatic (OS)</option><option value="documenter-light">documenter-light</option><option value="documenter-dark">documenter-dark</option><option value="catppuccin-latte">catppuccin-latte</option><option value="catppuccin-frappe">catppuccin-frappe</option><option value="catppuccin-macchiato">catppuccin-macchiato</option><option value="catppuccin-mocha">catppuccin-mocha</option></select></div></p><hr/><p>This document was generated with <a href="https://github.com/JuliaDocs/Documenter.jl">Documenter.jl</a> version 1.14.1 on <span class="colophon-date" title="Sunday 12 October 2025 06:38">Sunday 12 October 2025</span>. Using Julia version 1.9.4.</p></section><footer class="modal-card-foot"></footer></div></div></div></body></html>
